Table 1.

Approved Bispecific Antibodies in Oncology.

S No.	NCT	N	Phase	Target	Therapy	Trade Name	Indication	Approval Date	Approved by
1	NCT00836654	24	I/II	CD3/EpCAM	Catumaxomab	Removab	Malignant Ascites	April 2009	EMA
2	NCT01209286	36	II	CD3/CD19	Blinatumomab	Blincyto	Relapsed/Refractory B-cell ALL	December 2014	FDA
3	NCT02609776	362	I	MET/EGFR	Amivantamab	Rybrevant	EGFR Exon20ins NSCLC	May 2021	FDA
4	NCT03070392	378	II	CD3/TCR	Tebentafusp-tebn	Kimmtrak	Metastatic uveal melanoma	January 2022	FDA
5	NCT02500407	238	I/II	CD20/CD3	Mosunetuzumab	Lunsumio	Relapsed/Refractory B-cell lymphoma	June 2022	FDA
6	NCT04868708	45	I	PD-1/CTLA-4	Candonilimab		Recurrent/Metastatic cervical cancer	June 2022	NMPA
7	NCT03145181 NCT04557098	165	I/II	CD3/BCMA	Teclistamab-cqyv	Tecvayli	Relapsed/Refractory Multiple Myeloma	October 2022	FDA
8	NCT03625037	148	I/II	CD3/CD20	Epcoritamab-bysp	Epkinly	Relapsed/Refractory DLBCL	May 2023	FDA
9	NCT03075696	132	I/II	CD3/CD20	Glofitamab-gxbm	Columvi	Relapsed/Refractory DLBCL or large B-cell lymphoma	June 2023	FDA
10	NCT04649359	97	II	CD3/BCMA	Elranatamab-bcmm	Elrexfio	Relapsed/Refractory Multiple Myeloma	August 2023	FDA

Abbreviations: N—Number; CD—cluster of differentiation; cMet—C-mesenchymal-epithelial transition factor; CTLA-4—Cytotoxic T-Lymphocyte Antigen-4; EGFR—Epidermal Growth Factor Receptor; PD-1—programmed cell death 1; BCMA—B-cell maturation antigen; TCR—T-cell Receptor; EMA—European Medicines Agency; FDA—U.S. Food and Drug Administration; NMPA—National Medical Products Administration, DLBCL—diffuse large B-cell lymphoma; BCMA—B-cell maturation antigen.